Monoclonal antibody and vaccine targeting filamentous bacteriophage
AssigneeInimmune Corporation
InventorsPaul L. Bollyky, William Parks, Patrick Secor
Life of this patent
Estimating the term…
Abstract
Described here is a method for reducing or preventing Pseudomonas aeruginosa biofilm formation in a human subject in need thereof, comprising administering to the human subject a first composition comprising (a) an antigen-binding polypeptide that binds Pf-family bacteriophage, or (b) a vaccine against Pf-family bacteriophage. Also described is an antigen-binding polypeptide that binds specifically to a CoaB protein of Pf-family bacteriophage or fragment thereof.
Claims2
A method of inhibiting Pseudomonas aeruginosa biofilm formation in an animal or a human subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of one or more antibodies targeting a CoaB protein of Pf4 bacteriophage or an antigenic fragment thereof, wherein the one or more antibodies comprises:
- a heavy chain variable region comprising:
- (1) the CDR-H1 comprising the amino acid sequence of GFTFSSYV (SEQ ID NO:
- 6);
- (2) the CDR-H2 comprising the amino acid sequence of ISSGGST (SEQ ID NO:
- 7);
- and (3) the CDR-H3 comprising the amino acid sequence of LRGQDYGAAY (SEQ ID NO:
- 8) and
- a light chain variable region comprising:
- (1) the CDR-L1 comprising the amino acid sequence of QSLLDSDGKTY (SEQ ID NO:
- 9);
- (2) the CDR-L2 comprising the amino acid sequence of LVS (SEQ ID NO:
- 10);
- and (3) the CDR-L3 comprising the amino acid sequence of WQGTHFPQT (SEQ ID NO:
- 11);
- a heavy chain variable region comprising:
- (1) the CDR-H1 comprising the amino acid sequence of GYSFTSYW (SEQ ID NO:
- 16);
- (2) the CDR-H2 comprising the amino acid sequence of IYPGNSDT (SEQ ID NO:
- 17);
- and (3) the CDR-H3 comprising the amino acid sequence of TRSQFYSGSSEDAMDY (SEQ ID NO:
- 18) and
- a light chain variable region comprising:
- (1) the CDR-L1 comprising the amino acid sequence of QSIVHSNGNTY (SEQ ID NO:
- 19);
- (2) the CDR-L2 comprising the amino acid sequence of KVS (SEQ ID NO:
- 20);
- and (3) the CDR-L3 comprising the amino acid sequence of FQGSHVPWT (SEQ ID NO:
- 21);
- a heavy chain variable region comprising:
- (1) the CDR-H1 comprising the amino acid sequence of GYTFTNYG (SEQ ID NO:
- 26);
- (2) the CDR-H2 comprising the amino acid sequence of INTNTGEP (SEQ ID NO:
- 27);
- and (3) the CDR-H3 comprising the amino acid sequence ofARKDYRYWFAY (SEQ ID NO:
- 28) and
- a light chain variable region comprising:
- (1) the CDR-L1 comprising the amino acid sequence of QSIVHSNGNTY (SEQ ID NO:
- 29);
- (2) the CDR-L2 comprising the amino acid sequence of KVS (SEQ ID NO:
- 30);
- and (3) the CDR-L3 comprising the amino acid sequence of FQGSHVPFT (SEQ ID NO:
- 31).
Dependencies are inferred from the claim text.